Liposomal And Nanoparticle Technology At Pfizer Melbourne

Pfizer Melbourne is home to a cutting-edge liposomal and nanoparticle facility, purpose-built to accelerate the market entry of pre-commercial products. Engineered with flexibility at its core, the site accommodates a wide range of processing modalities and multiple equipment trains, enabling the efficient manufacture of intermediates, liposomes, and nanoparticles.

Leveraging Pfizer’s decades of global expertise in liposomal research, the facility translates scientific innovation seamlessly into both clinical and commercial-scale manufacturing. Thoughtfully designed to integrate clinical and commercial production under a single footprint, Pfizer Melbourne streamlines the transition from laboratory to patient, simplifying scale-up and ensuring consistency throughout the process.

The site supports a diverse portfolio of therapies, spanning high-potency oncology treatments to anti-infective medicines. Equipped with four aseptic filling lines and advanced fill-finish technologies, Pfizer Melbourne ensures precision, safety, and reliability in every dose. This combination of state-of-the-art infrastructure, scientific excellence, and operational flexibility makes the site a key hub for bringing innovative therapeutics from concept to patients efficiently and safely.